MOLECULIN BIOTECH, INC. (MBRX)
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
📈 **POSITIVE** • Medium confidence analysis (73%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (91%) **Content type:** Clinical